Immunosuppressive Activin-A signaling in melanoma and possibly other cancers is likely clinically relevant because elevated INHBA expression correlates with resistance to immune checkpoint blockade (ICB) therapy in melanoma patients and impairs the response to both ICB and T cell-based immunotherapy in mouse melanoma grafts (17). The gene discussed is INHBA; the disease is cancer.